A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

Fear of relapse and worsening disease is common for MS patients, leading to poorer mental health, per a study calling for ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Researchers are continuing to explore how the CXCL13-to-BAFF ratio can be used to advance precision medicine for people with multiple sclerosis.

The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.

A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis.

New research reveals that when gut bacteria closely resemble the myelin sheath that protects nerve fibers, the immune system can become confused and attack both — accelerating multiple sclerosis.

By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.

The progression of relapsing-onset multiple sclerosis (MS) and its associated disability may be slowing, results from a large population-based study suggest. In an evaluation of more than 7000 ...